载脂蛋白A-Ⅳ的抗氧化和抗炎作用

doi:10.3969/j.issn.1674-490X.2019.02.002

摘要/Abstract

摘要： 人载脂蛋白A-Ⅳ(apolipoprotein A-IV,ApoA-IV)主要由小肠和下丘脑合成分泌的一种含376氨基酸的46 ku糖蛋白,参与高密度脂蛋白的组成或以游离状态存在于血浆;ApoA-Ⅳ的遗传多态性中以Q360H和T347S两个亚型最常见;ApoA-Ⅳ不仅可介导反向胆固醇转运,而且有抗氧化和抗炎特性,因此循环ApoA-Ⅳ是一种脂质抗氧化剂和抗炎蛋白,在抗动脉粥样硬化中起重要作用。

关键词: 载脂蛋白A-Ⅳ, 动脉粥样硬化, 抗炎, 抗氧化

Abstract: Human apolipoprotein A-Ⅳ(ApoA-Ⅳ)is a 46 ku glycoprotein containing 376 amino acids mainly synthesized by the small intestine and hypothalamus, which participates in the composition of HDL or exists in plasma in a free state. Among the genetic polymorphisms of ApoA-IV, two subtypes of Q360H and T347S are the most common;ApoA-Ⅳ not only mediates reverse cholesterol transport, but also has antioxidant and anti-inflammatory properties, so circulating ApoA-Ⅳ is a lipid antioxidant and anti-inflammatory protein that acts in anti-AS important role.

Key words: apolipoprotein A-Ⅳ(ApoA-Ⅳ), atherosclerosis, anti-inflammatory, anti-oxidation

中图分类号:

R543

王铎,柳太云. 载脂蛋白A-Ⅳ的抗氧化和抗炎作用[J]. 医学研究与教育, 2019, 36(2): 8-12.

参考文献

[1] LOZHKIN A,VENDROV A E,PAN H,et al. NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis[J]. J Mol Cell Cardiol,2017,102:10-21. DOI: 10.1016/j.yjmcc.2016.12.004.
[2] MARTINON F. Signaling by ROS drives inflammasome activation[J]. Eur J Immunol,2010,40(3):616-619. DOI: 10.1002/eji.200940168.
[3] REUTER S,GUPTA S C,CHATURVEDI M M, et al. Oxidative stress, inflammation, and cancer: how are they linked?[J].Free Radic Biol Med,2010,49(11):1603-1616. DOI: 10.1016/j.freeradbiomed.2010.09.006.
[4] DALLINGA-THIE G M,GROOT P H,VAN TOL A.Distribution of apolipoprotein A-Ⅳ among lipoprotein subclasses in rat serum[J].J Lipid Res,1985, 26(8): 970-976.
[5] KALOGERIS T J,RODRIGUEZ M D,TSO P.Control of synthesis and secretion of intestinal apolipoprotein A-Ⅳ by lipid[J].J Nutr,1997, 127(3):537S-543S.
[6] WANG F,KOHAN A B,LO C M,et al. Apolipoprotein A-Ⅳ: a protein intimately involved in metabolism[J].J Lipid Res,2015,56(8):1403-1418. DOI: 10.1194/jlr.R052753.
[7] PENG J,LI X P. Apolipoprotein A-Ⅳ: a potential therapeutic target for atherosclerosis[J]. Prostaglandins Other Lipid Mediat,2018,139:87-92. DOI: 10.1016/j.prostaglandins.2018.10.004.
[8] YANG X, LI Y, LI Y,et al. Oxidaive stress-mediated atherosclerosis: mechanisms and therapies[J]. Front Physiol,2017,8:600. DOI: 10.3389/fphys.2017.00600.
[9] DUVERGER N,TREMP G,CAILLAUD J M,et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-Ⅳ[J].Science,1996, 273(5277):966-968.
[10] QIN X,SWERTFEGER D K,ZHENG S,et al.Apolipoprotein A-Ⅳ:a potent endogenous inhibitor of lipid oxidation[J].Am J Physiol,1998, 274(5Pt2):H1836-H1840.
[11] OSTOS M A,CONCONI M,VERGNES L,et al.Antioxidative and antiatherosclerotic effects of human apolipoprotein A-Ⅳ in apolipoprotein E-deficient mice[J].Arterioscler Thromb Vasc Biol,2001, 21(6):1023-1028.
[12] WONG W M,GERRY A B,PUTT W,et al.Common variants of apolipoprotein A-Ⅳ differ in their ability to inhibit low density lipoprotein oxidation[J].Atherosclerosis,2007, 192(2):266-274. DOI: 10.1016/j.atherosclerosis.2006.07.017.
[13] SPAULDING H L,SAIJO F,TURNAGE R H,et al.Apolipoprotein A-Ⅳ attenuates oxidant-induced apoptosis in mitotic competent,undifferentiated cells by modulating intracellular glutathione redox balance[J].Am J Physiol Cell Physiol,2006,290(1):C95-C103. DOI: 10.1152/ajpcell.00388.2005.
[14] RECALDE D,OSTOS M A,BADELL E,et al.Human apolipoprotein A-Ⅳreduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide[J].Arterioscler Thromb Vasc Biol,2004, 24(4):756-761. DOI: 10.1161/01.ATV.0000119353.03690.22.
[15] WONG W M,STEPHENS J W,ACHARYA J,et al.The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease[J].J Lipid Res,2004, 45(8): 1565-1571. DOI: 10.1194/jlr.M400130-JLR200.
[16] ARNOLD N,KOENIG W. Atherosclerosis as an inflammatory disease-pathophysiology,clinical relevance and therapeutic implications[J].Dtsch Med Wochenschr, 2019,144(5):315-321. DOI: 10.1055/a-0657-1595.
[17] SHAH P K. Inflammation, infection and atherosclerosis[J]. Trends Cardiovasc Med,2019, pii: S1050-1738(19)30004-0. DOI: 10.1016/j.tcm.2019.01.004.
[18] HEDIN U,MATIC L P.Recent advances in therapeutic targeting of inflammation in atherosclerosis[J]. J Vasc Surg,2019,69(3):944-951. DOI: 10.1016/j.jvs.2018.10.051.
[19] KOBIYAMA K,LEY K. Atherosclerosis[J]. Circ Res,2018,123(10):1118-1120. DOI: 10.1161/CIRCRESAHA.118.313816.
[20] NASONOV E L,POPKOVA T V. Atherosclerosis: perspectives of anti-inflammatory therapy[J]. Ter Arkh,2018,90(5):4-12. DOI: 10.26442/terarkh201890514-12.
[21] VOWINKEL T,MORI M,KRIEGLSTEIN C F,et al.Apolipoprotein A-Ⅳ inhibits experimental colitis[J]. J Clin Invest,2004, 114(2):260-269. DOI: 10.1172/JCI21233.
[22] GERONIMO F R B,BARTER P J,RYE K A,et al. Plaque stabilizing effects of apolipoprotein A-Ⅳ[J]. Atherosclerosis,2016,251:39-46. DOI: 10.1016/j.atherosclerosis.2016.04.019.
[23] CANALES A,SÁNCHEZ-MUNIZ F J,BASTIDA S,et al.Effect of walnut-enriched meat on the relationship between VCAM,ICAM,and LTB4 levels and PON-1 activity in ApoA4 360 and PON-1 allele carriers at increased cardiovascular risk[J].Eur J Clin Nutr,2011, 65(6):703-710. DOI: 10.1038/ejcn.2011.20.
[24] CHELBI S T,WILSON M L,VEILLARD A C,et al.Genetic and epigenetic mechanisms collaborate to control SERPINA3 expression and its association with placental diseases[J]. Hum Mol Genet,2012,21(9):1968-1978. DOI: 10.1093/hmg/dds006.
[25] 潘徐彪,李向玉,王志鑫,等. NLRP3(Caspase-1)/IL-1β 信号通路的研究进展[J]. 中国医药导报,2019,16(1):41-44.
[26] ZHANG Y,HE J,ZHAO J,et al. Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes[J]. Biochem Biophys Res Commun,2017,487(2):327-332. DOI: 10.1016/j.bbrc.2017.04.058.
[27] PENG J, LI X P. Apolipoprotein A-Ⅳ may inhibit inflammation via regulating NLRP3/IL-1 path to anti-atherosclerosis[J]. Int J Cardiol,2019,278:223. DOI: 10.1016/j.ijcard.2018.11.103.
[28] MAKINO Y,NOGUCHI E,TAKAHASHI N,et al.ApolipoproteinA-Ⅳ is a candidate target molecule for the treatment of seasonal allergic rhinitis[J].J Allergy Clin Immunol,2010, 126(6):1163-1169. DOI: 10.1016/j.jaci.2010.06.031.
[29] KRONENBERG F,STÜHLINGER M,TRENKWALDER E,et al. Low apolipoprotein A-Ⅳ plasma concentrations in men with coronary artery disease[J].J Am Coll Cardiol,2000, 36(3):751-757.
[30] EZEH B,HAIMAN M,ALBER H F,et al.Plasma distribution of apoA-Ⅳ in patients with coronary artery disease and healthy controls[J].J Lipid Res,2003, 44(8): 1523-1529. DOI: 10.1194/jlr.M300060-JLR200.
[31] LI J,SONG M,QIAN D,et al. Decreased plasma apolipoprotein A-Ⅳ levels in patients with acute coronary syndrome[J]. Clin Invest Med, 2013,36(4):E207-E215.
[32] FLORES-NASCIMENTO M C,PAES-LEME A F,MAZETTO B M,et al. Inflammatory, immune and lipid transportation proteins are differentially expressed in spontaneous and proximal deep vein thrombosis patients[J].Thromb Res,2012, 130(5): e246-e250. DOI: 10.1016/j.thromres.2012.08.306.
[33] REWERS M,KAMBOH M I,HOAG S,et al. ApoA-Ⅳ polymorphism associated with myocardial infarction in obese NIDDM patients. The San Luis Valley Diabetes Study[J].Diabetes,1994, 43(12):1485-1489.
[34] EJCHEL T F,ARAU 'JO L M,RAMOS L R,et al.Association of the apolipoprotein A-Ⅳ: 360 Gln/His polymorphism with cerebrovascular disease, obesity, and depression in a Brazilian elderly population[J].Am J Med Genet B Neuropsychiatr Genet,2005, 135B(1): 65-68. DOI: 10.1002/ajmg.b.30175.